Table 3.

Frequency, detailed combination patterns, progression-free survival, overall survival and response to first-generation TKIs of compound EGFR mutations

Subgroup of compound EGFR mutations	Frequency (n,  %)	Mutated exons	Response (rate, %)	PFS (range, months)	OS (range, months)
Double common	5 (4.7)		25.0%	10.1 ± 2.4	24.2 ± 8.2
19Del + L858R	5	19 and 21	3PR, 1SD, 1PD	4.9–12	13.1–25.6
Common + rare	11 (10.4)		45.5%	10.5 ± 3.9	Not reached
19Del + L861Q	2	19 and 21	1PR, 1SD	11.9–14.4	26.5–41.2
L858R + S720P	1	21 and 18	PD	2.1	2.1
L858R + K757R	1	21 and 19	PR	9.0	8.7
L858R + I744 M	1	21 and 19	PR	17.6	41.2
L858R + S768I	3	21 and 20	1PR, 1PD, 1SD	1.8–6.2	4.0–12.5
L858R + R776H	1	21 and 20	PR	10.5	12.6
L858R + L858Q	1	21 and 21	NE	1	3
L858R + L833V	1	21 and 21	SD	5.0	15.9
Common + T790M	69 (65.1)		56.5%	10.3 ± 0.6	Not reached
19Del + T790M	43	19 and 20	27PR, 12SD, 2 PD, 2NE	0.6–40.7	0.2–88.5
L858R + T790M	26	21 and 20	12PR, 10SD, 3PD, 1NE	0.9–24.1	1.2–56.6
Rare + rare	13 (12.3)		38.5%	6.5 ± 1.3	Not reached
G719C + S768I	1	18 and 20	PR	6.5	13.2
G719S + S768I	2	18 and 20	1PR, 1SD	1–8.0	2.0–8.4
G719S + L858Q	1	18 and 21	SD	6.4	29.3
G719X + S768I	3	18 and 20	2PR, 1SD	2.0–18	2.0–44.0
G719X + L858Q	3	18 and 21	1SD, 1PD, 1NE	0.3–27.3	2.3–29.2
G719S + E709A	1	18 and 18	PR	4.1	4.1
G719S + L858Q	1	18 and 21	SD	6.4	29.3
S768I + V774M	1	20 and 20	PD	2.0	13.8
Rare + T790M	8 (7.5%)		37.5%	5.4 ± 2.5	23.8 ± 1.5
G719X + T790M	1	18 and 20	PR	11.1	55.6
D761Y + T790M	2	19 and 20	2PD	1.1–5.5	1.1–8.5
L858Q + T790M	5	21 and 20	2PR, 1SD, 2PD	1.4–20.6	18–88.3

TKI tyrosine kinase inhibitor, PFS progression-free survival, OS overall survival, PR partial response, SD stable disease, CR complete response, PD progressive disease, NE not evaluated